CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

Negative
AI Analysis

Summary

Analyst downgrades Alkermes due to competitive pressures from Takeda and Lilly in the orexin market, despite acknowledging the upside potential of the company's orexin program.

Importance:3/10
Sentiment:
-0.60
competitive_analysisdowngradeorexin_program
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 23, 2026 2:19 PM

Read Original